Location of GLP-1 Release

Background: Physicians do not have a unified, scientifically tested theory of causation for obesity and its comorbidities, nor do they have explanations for the mechanics of the metabolic/bariatric surgery procedures. Integral to proffered hypotheses are the actions of the hormones glucagon-like peptide (GLP-1), peptide YY (PYY), and leptin.

Study objective: To obtain blood levels of GLP-1, PYY, and leptin after stimulation of the terminal ileum and cecum by a static infusion of a food hydrolysate in morbidly obese patients undergoing a duodenal switch procedure.

Methods: Plasma levels of GLP-1, PYY, and leptin were obtained at 0, 30, 60, 90, and 120 minutes after instillation of 240 ml of a food hydrolysate into the ileum or cecum.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Any patient who was qualified and approved for bariatric surgery and elected to undergo open duodenal switch procedure.

Exclusion criteria

Treatment and study plan

Primary outcomes

GLP-1

Time frame: 2 hours

GLP- levels were measured at intervals over two hours after static bowel food hydrolysate was infused, in patients undergoing scheduled open duodenal switch procedure.
peptide YY (PYY)

Time frame: 2 hours

PYY levels were measured at intervals over two hours after static bowel food hydrolysate was infused, in patients undergoing scheduled open duodenal switch procedure.
Leptin

Time frame: 2 hours

Leptin levels were measured at intervals over two hours after static bowel food hydrolysate was infused, in patients undergoing scheduled open duodenal switch procedure.

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Official study title

Location of Glucagon-Like Peptide (GLP)-1 Release

Important dates

Study start: 2011
Primary completion: 2013
Study completion: 2013
First posted: Jan 15, 2014
Registry last updated: Nov 1, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed